HTAs and rare diseases: How to assess their cost-effectiveness

Pharmaceuticals Policy and Law

Volumn 13, Issue 3-4, 2011, Pages 161-165

  Phillips, Ceri J ^a   Hughes, Dyfrig A ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85013587254     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: 10.3233/PPL-2011-0321     Document Type: Article

References (14)

1. D.A. Hughes, B. Tunnage and S.T. Yeo, Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM 98 (2005), 829-836.
2. C.McCabe, K. Claxton and A. Tsuchiya, Orphan drugs and the NHS: should we value rarity? BMJ 331 (2005), 1016. doi: 10.1136/bmj.331.7523.1016.
3. D.A. Hughes, Rationing of drugs for rare diseases, Pharmacoeconomics 24 (2006), 315-316.
4. D.F. Moore, M. Ries, E.L. Forget and R. Schiffmann, Enzyme replacement therapy in orphan and ultra-orphan diseases: the limitations of standard economic metrics as exemplified by Fabry-Anderson disease, Pharmacoeconomics 25 (2007), 201-208.
5. M.F. Drummond, D.A. Wilson, P. Kanavos, P. Ubel and J. Rovira, Assessing the economic challenges posed by orphan drugs, International Journal of Technology Assessment in Health Care 23 (2007), 36-42.
6. R.E. Ferner and D.A. Hughes, The problem of orphan drugs, BMJ 341 (2010), c6456. doi: 10.1136/bmj.c6456.
7. National Institute for Health and Clinical Excellence. Appraising life-extending, end of life treatments. Available at: http://www.nice.org.uk/media/E4A/79/SupplementaryAdviceTACEoL.pdf (accessed 18/06/2011).
8. J.McKie, B. Shrimpton, J. Richardson and R. Hurworth, Themonetary value of a life year: evidence from a qualitative study of treatment costs, Health Econonomics, doi: 10.1002/hec.1660.
9. J.McKie and J. Richardson, The rule of rescue, Social Science and Medicine 56 (2003), 2407-2419.
10. P. Dolan, R. Shaw, A. Tsuchiya and A. Williams, QALY maximisation and people’s preferences: a methodological review of the literature, Health Economics 14 (2005), 197-208.
11. M. Gross, Ethics, policy and rare genetic disorders: the case of Gaucher disease in Israel, Theor Med Bioeth 23 (2002), 151-171.
12. NICE Citizens’ Council, Ultra Orphan Drugs, http://www.nice.org.uk/niceMedia/pdf/boardmeet ing/brdjan05item4.pdf (accessed 19/06/2011).
13. A.S. Desser, D. Gyrd-Hansen, J.A. Olsen, S. Grepperud and I.S. Kristiansen, Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67, BMJ 341 (2010), c4715. doi: 10.1136/bmj.c4715.
14. All Wales Medicines Strategy Group, AWMSG guidelines for appraising medicines. http://www. wales.nhs.uk/sites3/Documents/371/Guidelines%20for%20appraising%20medicines.pdf (accessed 19/06/2011).